PMV Pharmaceuticals, Inc. (PMVP) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-52.3%

$0.65

vs $1.37 price

Levered DCF

$0.71

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

-6.12

Distress zone

Rating

B-

Overall 3 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-0.84×	-1.33×	-2.15×	-5.4×	-18.05×	-25.63×	-63.58×	-6.47×
P/B	0.63×	0.44×	0.66×	1.61×	3.38×	7.67×	-22.89×	-2.46×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-0.36×	-0.52×	-1.84×	-4.14×	-15.32×	-70.14×	-61.69×	-10.26×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	10.09×	12.22×	14.78×	22.8×	24.66×	56.9×	22.57×	26.75×
Debt / equity	0.01×	0.01×	0.06×	0.06×	0.04×	0×	0×	-2.32×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-74.2%	-33.3%	-30.6%	-29.8%	-18.7%	-9.6%	36.0%	38.0%
Return on invested capital	-79.5%	-37.8%	-33.5%	-29.6%	-18.2%	-9.7%	-27.0%	-30.9%
Return on assets	-66.7%	-30.7%	-27.3%	-27.1%	-17.4%	-9.4%	-24.6%	-27.6%
Free cash flow yield	-112.1%	-66.7%	-38.0%	-18.1%	-4.6%	-1.2%	-1.4%	-13.8%
Earnings yield	-118.4%	-75.4%	-46.3%	-18.5%	-5.5%	-1.3%	-1.6%	-15.5%
Enterprise value	$28.5M	$38.2M	$124.4M	$302.4M	$881.4M	$2.4B	$1.5B	$190.4M
Net debt / EBITDA	0.47×	0.54×	0.36×	1.29×	2.8×	10.59×	2.94×	-4.15×
Cash conversion cycle (days)	0	-2,099	-940	-1,682	-909	-1,845	-2,669	-1,121